#United States #California #Class Action #Pomerantz LLP #Aardvark Therapeutics

Pomerantz Law Firm Files a Class Action Lawsuit Against Aardvark Therapeutics

In a significant legal development, Pomerantz LLP has announced the filing of a class action lawsuit against Aardvark Therapeutics, Inc. This lawsuit, lodged in the United States District Court for the Southern District of California, brings serious allegations against the clinical-stage biopharmaceutical company and its executive team.

Background of the Lawsuit

The class action, designated under docket number 26-cv-04643, aims to represent all individuals and entities who purchased or acquired Aardvark stock as per the Offering Documents issued during the company’s initial public offering (IPO) on February 13, 2025. The complaint specifies that the class includes all shares acquired between February 13, 2025, and May 14, 2026, inclusive. Plaintiff claims that the Defendants violated securities laws by failing to disclose critical information regarding the company’s product candidates and their safety evaluations, thus misleading investors.

Seeking Justice for Investors

Investors who purchased Aardvark common stock as outlined in the Offering Documents are encouraged to act quickly. They have until October 13, 2026, to apply to the court to become Lead Plaintiff for the class. Those interested can obtain a copy of the complaint from Pomerantz's website and are advised to contact Danielle Peyton for further assistance.

Aardvark Therapeutics: Company Overview

Aardvark Therapeutics is focused on developing innovative therapies for metabolic diseases, particularly targeting conditions like Prader-Willi Syndrome (PWS), characterized by an insatiable hunger condition known as hyperphagia. The company claims to develop unique small-molecule treatments aimed at addressing hunger through innovative mechanisms involving Bitter Taste Receptors (TAS2Rs).

The Role of ARD-101

The company’s lead product candidate, ARD-101, is designed to act as an agonist to these receptors, potentially inducing endogenous signaling that might help in appetite regulation. Aardvark’s research claims that by activating these receptors, the body can stimulate the release of significant molecules like cholecystokinin (CCK), which is believed to play a critical role in suppressing hunger.

The IPO and Allegations of Misleading Information

Aardvark’s IPO raised substantial funds, generating nearly $88 million by selling approximately 5.89 million shares at $16.00 each after underwriter discounts. However, the class action alleges that the Offering Documents were improperly prepared. They purportedly contained misleading statements or omitted material facts, thus contravening regulations governing such disclosures. Throughout the class period, significant claims were made about the safety and commercial prospects of ARD-101, which have now come under scrutiny.

Emergence of the Truth

The situation escalated on February 27, 2026, when Aardvark revealed that it was voluntarily pausing the Phase 3 HERO trial due to cardiac concerns that arose during safety monitoring. This caused a dramatic decline in the company’s stock price, triggering alarms among investors. Following this disclosure, shares plummeted by over 56%, reflecting an erosion of investor confidence.

An Ongoing Investigation

The litigation portrays a grim picture for Aardvark; following the revelation about the clinical hold imposed by the FDA for ARD-101, the shares fell further, indicating an environment of uncertainty fueled by previously undisclosed risks. As events unfold, the legal ramifications could reshape the landscape for Aardvark and its investors.

Pomerantz LLP: A Leader in Class Action Complaints

Pomerantz LLP has established itself as a leader in the realm of corporate litigation, particularly in securities class actions. With a history dating back more than 85 years, the firm prides itself on championing the rights of investors and seeking restitution for those adversely impacted by corporate malpractice.

For those affected by this situation, it is imperative to stay updated and consider the options available through Pomerantz’s legal pathways. For further inquiries, potential class members can connect with the firm directly.

Regaining justice for investors while pressuring corporate governance standards remains a prime focus, reflecting broader trends in investor activism and heightened scrutiny on public companies across all sectors.